October 2018 - Cancer Currents Blog
- Immunotherapy Drug Cemiplimab Approved for Advanced Squamous Cell Skin Cancer
The Food and Drug Administration approved the immunotherapy drug cemiplimab (Libtayo) for an advanced form of cutaneous squamous cell carcinoma (SCC), a common type of skin cancer. It is the first agent to be approved specifically for advanced SCC.
- Trial Results Highlight Changing Lung Cancer Treatment Landscape
Results from two large clinical trials should cement the value of the drugs brigatinib (Alunbrig) and durvalumab (Imfinzi) in treating non-small cell lung cancer (NSCLC). The trial results, several experts said, confirm that the drugs can improve the outcomes of patients with advanced NSCLC.
- For HPV-Positive Women, Test Can Guide Cervical Cancer Screening Follow-Up
A new test can help to improve the clinical management of women who screen positive for HPV infection during routine cervical cancer screening, an NCI-led study has shown.
- Using Artificial Intelligence to Classify Lung Cancer Types, Predict Mutations
Cancer researchers have trained a computer program to scan images of tissue samples to differentiate normal lung tissue from the two most common forms of lung cancer. The program also learned to detect cancer-related genetic mutations in the samples.
- Vaping Pods Produce High Nicotine Levels in Young Users
Adolescents who use pod-style e-cigarettes had higher levels of nicotine in their bodies than is typically found in adolescents who smoke conventional cigarettes, a new study has found. The study's findings are concerning for several reasons.
- For Small Cell Lung Cancer, Immunotherapy Drug Finally Brings Improved Survival
In a large clinical trial, the immunotherapy drug atezolizumab (Tecentriq), combined with a standard chemotherapy regimen, modestly increased survival in patients with advanced small cell lung cancer (SCLC). The trial is the first in more than 20 years to show a survival improvement in this cancer.